ExCellThera Announces UM171 Data to be Presented at ASH 2023
ExCellThera Inc. (ExCellThera), a global leader in blood stem cell expansion and fitness, has revealed that it will be presenting new data on UM171 cell therapy at the 65th American Society of Hematology Annual Meeting & Exposition (ASH) in December 2023. The presentations will include an oral session on Phase 2 studies of investigational UM171 cell therapy in high-risk blood cancer patients. The abstracts for these presentations are now available on the ASH website.
UM171 Cell Therapy
UM171 Cell Therapy has undergone evaluation in over 100 patients as a treatment for hematologic malignancies in clinical trials across the United States, Europe, and Canada. It has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designation from the FDA, as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification, and priority medicines (PRIME) designation from the EMA. It is important to note that UM171 Cell Therapy is still an investigational cell therapy, and its safety and efficacy have not been established by health authorities.
ExCellThera is a leading company specializing in blood stem cell expansion and fitness. Their proprietary EnhanceTM platform is designed to increase the dose of functional therapeutic stem cells by expanding HSCs from any source and mitigating the effects of culture or gene editing-induced stress. ExCellThera collaborates with bio-pharmaceutical companies to develop cutting-edge cell and gene therapies, leveraging the technologies of the EnhanceTM platform, including the unique molecule UM171, which has a first-in-class mechanism of action for ex vivo expansion and fitness of HSCs. For more information, please visit excellthera.com and follow ExCellThera on LinkedIn.
ExCellThera's UM171 Data Presentation: A Game Changer for New Businesses in Biotech?
ExCellThera's announcement of presenting new UM171 cell therapy data at the 65th American Society of Hematology Annual Meeting & Exposition (ASH) in December 2023 could potentially shake up the biotech industry. This is particularly relevant for new businesses looking to make their mark in the field of blood stem cell expansion and fitness.
Impact on the Biotech Industry
The UM171 cell therapy, which is still under investigation, has already been evaluated in over 100 patients across the United States, Europe, and Canada. It has received significant recognition from both the FDA and the EMA, indicating its potential in treating hematologic malignancies. This could pave the way for new businesses to explore similar therapies and contribute to advancements in this field.
Opportunities for New Businesses
ExCellThera's EnhanceTM platform, designed to increase the dose of functional therapeutic stem cells, presents an innovative approach to cell and gene therapy. This could inspire new businesses to develop cutting-edge technologies and collaborate with bio-pharmaceutical companies, thereby driving growth and innovation in the biotech industry.
While the safety and efficacy of UM171 Cell Therapy are yet to be established, ExCellThera's upcoming presentation at ASH 2023 could potentially influence the direction of new businesses in the biotech industry. It underscores the importance of continuous research and collaboration in advancing medical science.